Manufacturer of Controlled Substances; Notice of Application, 21245 [05-8141]

Download as PDF Federal Register / Vol. 70, No. 78 / Monday, April 25, 2005 / Notices Drug rmajette on DSK29S0YB1PROD with NOTICES Dated: April 14, 2005. William J. Walker, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 05–8140 Filed 4–22–05; 8:45 am] Dated: April 14, 2005. William J. Walker, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 05–8141 Filed 4–22–05; 8:45 am] I BILLING CODE 4410–09–P BILLING CODE 4410–09–P I DEPARTMENT OF JUSTICE DEPARTMENT OF LABOR I I I I I I Drug Enforcement Administration Employment and Training Administration Manufacturer of Controlled Substances; Notice of Application [TA–W–56,168] Pursuant to Section 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on February 1, 2005, Penick, Corporation, 158 Mount Olivet Avenue, Newark, New Jersey 07114, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in Schedules II: AG Communication Systems, a Division of Lucent Technologies, Genoa, IL; Including Employees of AG Communication Systems, a Division of Lucent Technologies, Genoa, IL Working in the States of: TA–W– 56,168A Florida, TA–W–56,168B Wisconson, TA–W–56,168C California, TA-W–56,168D Texas; Amended Certification Regarding Eligibility To Apply for Worker Adjustment Assistance and Alternative Trade Adjustment Assistance Schedule N-Hydroxy-3,4methylenedioxyamphetamine (7402). 3,4-Methylenedioxy-Nethylamphetamine (7404). 3,4Methylenedioxymethamphetamine (7405). Alpha-methyltryptamine (AMT) (7432). Bufotenine (7433) ......................... Diethyltryptamine (7434) .............. Dimethyltyptamine (7435) ............ Psilocybin (7437) .......................... Psilocyn (7438) 5-methoxy-N-,Ndiisopropyltryptamine-(5-MeODIPT) (7439). N-Ethyl-1-phenylcyclohexylamine (7455). 1-(1-Phenylcyclohexyl) pyrrolidine (PCPy) (7458). 1[1-(2 Thienyl) cyclohexyl] piperidine (7470). Dihydromorphine (9145) ............... Normorphine (9313) ..................... Methamphetamine (1105) ............ 1-Phenylcylohexylamine (7460) ... Phencyclidine (7471) .................... Phenylacetone (8501) .................. 1Piperidinocyclohexanecarbonitrile (8603). Cocaine (9041) ............................. Codeine (9050) ............................. Dihydrocodeine (9120) ................. Benzoylecgonine (9180) ............... Ethylmorphine (9190) ................... Morphine (9300) ........................... Noroxymorphone (9668) .............. I I I I I I I II II II II II Drug 14:51 Oct 19, 2009 II II II II II II II Jkt 220001 Schedule Cocaine (9041) ............................. Codeine (9050) ............................. Dihydrocodeine (9120) ................. Oxycodone (9143) ........................ Hydromorphone (9150) ................ Ecgonine (9180) ........................... Hydrocodone (9193) ..................... Morphine (9300) ........................... Thebaine (9333) ........................... Oxymorphone (9652) ................... The company plans to manufacture small quantities of the listed controlled substances for reference standards. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Applied Science Labs to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Applied Science Labs to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. VerDate Nov<24>2008 21245 II II II II II II II II II II The company plans to manufacture the listed controlled substances in bulk for distribution to its customers. Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections being sent via regular mail may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative, Liaison and Policy Section (ODL); or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than June 24, 2005. PO 00000 Frm 00073 Fmt 4703 Sfmt 4703 In accordance with Section 223 of the Trade Act of 1974 (19 U.S.C. 2273) the Department of Labor issued a Certification of Eligibility to Apply for Worker Adjustment Assistance and Alternative Trade Adjustment Assistance on January 4, 2005, applicable to workers of AG Communication Systems, a division of Lucent Technologies, Genoa, Illinois. The notice was published in the Federal Register on February 7, 2005 (70 FR 6460). At the request of the State agency, the Department reviewed the certification for workers of the subject firm. New information shows that worker separations have occurred involving employees of AG Communication Systems, a division of Lucent Technologies, Genoa, Illinois working in Florida, Wisconsin, California and Texas. These employees provide support function services for the production of telecommunications equipment produced at the Genoa, Illinois location of the subject firm. Based on these findings, the Department is amending this certification to include employees of AG Communication Systems, a division of Lucent Technologies, Genoa, Illinois working in Florida, Wisconsin, California and Texas. The intent of the Department’s certification is to include all workers of AG Communication Systems, a division of Lucent Technologies who were adversely affected by a shift in production to Malaysia. E:\TEMP\25APN1.SGM 25APN1

Agencies

[Federal Register Volume 70, Number 78 (Monday, April 25, 2005)]
[Notices]
[Page 21245]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-8141]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Section 1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on February 1, 2005, Penick, 
Corporation, 158 Mount Olivet Avenue, Newark, New Jersey 07114, made 
application by renewal to the Drug Enforcement Administration (DEA) to 
be registered as a bulk manufacturer of the basic classes of controlled 
substances listed in Schedules II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Cocaine (9041).............................  II
Codeine (9050).............................  II
Dihydrocodeine (9120)......................  II
Oxycodone (9143)...........................  II
Hydromorphone (9150).......................  II
Ecgonine (9180)............................  II
Hydrocodone (9193).........................  II
Morphine (9300)............................  II
Thebaine (9333)............................  II
Oxymorphone (9652).........................  II
------------------------------------------------------------------------

    The company plans to manufacture the listed controlled substances 
in bulk for distribution to its customers.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such a substance may file comments or 
objections to the issuance of the proposed registration pursuant to 21 
CFR 1301.33(a).
    Any such written comments or objections being sent via regular mail 
may be addressed, in quintuplicate, to the Deputy Assistant 
Administrator, Office of Diversion Control, Drug Enforcement 
Administration, Washington, DC 20537, Attention: DEA Federal Register 
Representative, Liaison and Policy Section (ODL); or any being sent via 
express mail should be sent to DEA Headquarters, Attention: DEA Federal 
Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, 
Virginia 22301; and must be filed no later than June 24, 2005.

    Dated: April 14, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 05-8141 Filed 4-22-05; 8:45 am]
BILLING CODE 4410-09-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.